SynthesisJournal of neuro-oncology2025
Evaluating the role of gross total resection in primary spinal cord glioblastoma: evidence from a multicenter cohort and meta-analysis.
Synthesis in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Influence of treatment modalities on survival and progression free survival in primary spinal cord glioblastoma: a systematic review and individual participant data meta-analysis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary spinal cord glioblastoma (PscGB) is a rare, aggressive tumor that accounts for about 7.5% of spinal cord gliomas. Its infiltrative growth and proximity to critical neural structures make diagnosis and management challenging, and data on prognostic factors and optimal treatment remain limited.
objectiveTo evaluate the impact of the extent of surgical resection and adjuvant chemoradiotherapy on overall survival (OS) in PscGB, and to identify independent predictors of poor prognosis.
methodsA retrospective multicenter cohort was analyzed alongside a systematic review and meta-analysis of comparative clinical studies. Through stringent enrollment criteria, demographic, clinical, radiological, and surgical data were collected. The overall survival (OS) was the primary outcome. Survival outcomes were evaluated with Kaplan-Meier curves, while predictors of better OS were identified using univariate and multivariate least squares regression. For the meta-analysis, individual patient data were retrieved where available, and a random-effects model using hazard ratios (HR) assessed the effects of extent of resection and adjuvant therapy on survival.
resultsThe multicenter cohort (n = 13) and systematic review (n = 67) together included 80 operated PscGB patients. The meta-analysis combined data from five published comparative studies plus our institutional series, for a total of 111 patients. No significant difference in OS was observed among patients undergoing gross total resection, subtotal resection, or biopsy (HR = 0.68, 95% CI: 0.29-1.58; p = 0.37). In contrast, adjuvant chemoradiotherapy was significantly associated with improved survival (HR = 0.37, 95% CI: 0.17-0.78; p = 0.009). Multivariate analysis identified delayed surgery (p < 0.01) and absence of adjuvant chemoradiotherapy (p < 0.01) as independent predictors of poorer OS. Sensitivity and publication bias analyses supported the robustness of these findings.
conclusionIn this study, gross total resection did not provide a significant survival benefit in PscGB, while earlier surgery and adjuvant chemoradiotherapy were associated with improved outcomes. However, our findings are to be interpreted as merely observational and not conclusive and therefore should be observed with caution. Larger prospective studies are needed to confirm these results and inform clinical practice.
Indexed as
Identifiers
40670812What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.